靶向药培美替尼什么价位一盒？培美替尼售国内获批上市了吗？

It is a small molecule kinase inhibitor targeting FGFR1, 2, and 3, with an IC50 value of less than 2nM. In vitro, pemetinib also inhibits FGFR4 at approximately 100-fold higher concentrations than FGFR1, 2, and 3. Pemetinib constitutively activates FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signal transduction and reducing cell viability.

Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Pemetinib showed antitumor activity in mouse xenograft models of human tumors with altered FGFR1, FGFR2, or FGFR3, which resulted in constitutive FGFR activation, including expression of the oncogenic FGFR 2-Transformer-2β homolog (TRA2b) fusion protein in patients with cholangiocarcinoma xenograft models.

Pemetinib is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma as detected by an FDA-approved test.

Instructions are approved under expedited approval based on overall response rate and response time. Continued approval for this indication may be dependent on verification and description of clinical benefit in confirmatory trials.

What is the price of a box of the targeted drug pemetinib? Has pemetinib been approved for sale in China?

According to Medical Companion Travel, pemetinib has not yet been officially launched in China. Therefore, most patients use the foreign version. The foreign pemetinib specification is 13.5 mg x 14 tablets and the price is around 341,175$. Due to the floating exchange rate, the price is different. Please consult Medical Companion Travel for specific prices!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: